Clinical Literature
DFINE is committed to building scientific evidence to support the use of our products. Our latest therapeutic, the STAR™ Tumor Ablation System, received FDA 510(k) clearance in 2010, and is now involved in The Evaluation of Combined RF Ablation and Cement Delivery in Painful Tumors of the Spine Trial (AbCT). Data from the trial will be used to file for CE certification in Europe in 2012.
The AbCT Trial is the first prospective study to focus on the substantial palliative benefits of targeted tumor ablation and cement augmentation in the interventional oncology arena involving the spine. This therapeutic approach combines DFINE’s core technologies – radiofrequency energy, navigational instrumentation, and ultra-high viscosity bone cement – to create an extension of our RF platform. It represents a major milestone for cancer patients and for DFINE.
Moving forward the company continues to invest in clinical studies to further improve the quality of life for patients suffering from metastatic and vertebral pathologies.
Physicians' insights on RF Ablation
STAR Tumor Ablation Procedure